FDA Brief

Warning letters Drugs

FDA warning letter to

Apotex Inc.

High riskIssued Oct 31, 2025Posted Nov 4, 2025Center for Drug Evaluation and Research (CDER)

FDA cited Apotex's Richmond Hill sterile plant for failed investigations and aseptic contamination risks, prompting recalls.

What happened

FDA inspected Apotex Inc.'s drug manufacturing facility at 380 Elgin Mills Road East, Richmond Hill, Ontario, from April 28 to May 9, 2025. Investigators found that the company repeatedly re-ran leak tests until they passed instead of investigating failures, filled sterile products on equipment with unresolved integrity problems, and had deteriorated isolator gloves and gaskets, tape on covers, and inadequate environmental monitoring. After the inspection Apotex paused U.S. production of certain sterile products and recalled three ophthalmic solutions (azelastine, ketorolac, brimonidine/timolol) and one lot of lacosamide oral solution.

What FDA found

  1. The company did not properly investigate failed leak tests on its aseptic filling equipment, re-testing until results passed instead of finding the root cause.

    21 CFR 211.192
  2. It did not fully investigate container-closure failures, including a stability sample that leaked and corroded its cap liner, and took no market action at the time.

    21 CFR 211.192
  3. It did not investigate repeated excessive weight loss in stability samples of multiple products.

    21 CFR 211.192
  4. Aseptic areas and isolator equipment were not adequately cleaned, decontaminated and maintained, with discoloration, deteriorated gaskets, and tape used on covers.

    21 CFR 211.113(b) & 211.42(c)(10)
  5. Environmental monitoring was inadequate because critical aseptic areas lacked continuous particle monitoring and relied on a single probe facing away from open processing.

    21 CFR 211.113(b)
  6. Equipment used for spray drug products was shedding white particles onto surfaces, and an available design upgrade was not installed for nearly a year.

    21 CFR 211.67(a)

What FDA wants

FDA wants an independent assessment and remediation plan for the deviation investigation and CAPA systems, a contamination-hazard risk assessment of aseptic operations with a maintenance and oversight plan, a retrospective cleaning assessment, and a visual inspection remediation plan. The company must reply in writing within 15 working days.

Who should pay attention

  • brands and repackagers that buy finished sterile or ophthalmic products from this contract manufacturer
  • quality teams running aseptic filling operations with isolators or barrier systems
  • companies relying on container-closure integrity and leak-test data from suppliers

This is a summary. Read the original letter on fda.gov.

Apotex Inc.'s FDA history

Recalls in the last 12 months

Oct 7 Class II Apotex Corp.
Drug
Paroxetine Extended-Release Tablets, 37.5mg, 30-count bottle, Rx only, Manufactured by: Apotex Inc., Toronto, Ontario, Canada M9L 1T9, Manufactured for: Apotex Corp., Weston, Florida 33326, NDC 60505-1318-3
Failed dissolution specifications.
Sep 2 Class II Apotex Corp.
Drug
Paxil CR, Paroxetine, Extended-Release Tablets, 37.5mg, 30 count bottle, Rx only, Manufactured by: Apotex Inc., Toronto, Ontario, Canada M9L 1T9, Manufactured for: Apotex Corp., Weston, Florida 33326, NDC 60505-4379-3
Failed Dissolution Specifications; product failed to meet 24-month stability testing acceptance criteria
Apr 22 Class II Apotex Corp.
Drug
Desmopressin Nasal Spray, USP, 10 mcg/0.1 mL, 5 mL bottle (50 doses), Rx only, Mfg by: Apotek inc., Toronto, Ontario, Canada, M9L 1T9, Mfg for: Apotek Corp., Weston, FL 33326, NDC 60505-0815-0
Defective container: defect in a batch of bottle caps, specifically involving dislodged or missing cap liners.
Mar 25 Class II Apotex Corp.
Drug
Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution 0.2%/0.5%*, 5 mL, Rx Only, Sterile, Apotex Corp. Manufactured for: Apotex Corp., Weston, FL 33326, NDC 60505-0589-1.
Lack of Assurance of Sterility

Full company page

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk
  3. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk
  4. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk